1) Jefferson T, et al:Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev, 2014:CD008965, 2014[PMID:24718923]
2) Dobson J, et al:Oseltamivir treatment for influenza in adults:a meta-analysis of randomised controlled trials. Lancet, 385:1729-1737, 2015[PMID:25640810]
3) 沢井製薬株式会社:オセルタミビルカプセル75mg「サワイ」添付文書 https://med.sawai.co.jp/file/pr1_4619.pdf
4) 厚生労働省医薬・生活衛生局医薬安全対策課:抗インフルエンザウイルス薬の「使用上の注意」の改訂について. 2018 https://www.mhlw.go.jp/web/t_doc?dataId=00tc3603&dataType=1&pageNo=1
5) Huh K, et al:Oseltamivir and the Risk of Neuropsychiatric Events: A National, Population-based Study. Clin Infect Dis, 71:e409-e414, 2020[PMID:31996920]
6) Heneghan CJ, et al:Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ, 348:g2547, 2014[PMID:24811412]
7) Centers for Disease Control and Prevention:CDC Statement on Oseltamivir (Tamiflu(R))Resistance and Antiviral Recommendations. 2009 https://www.cdc.gov/media/pressrel/2009/s090109.htm
8) グラクソ・スミスクライン株式会社:リレンザ 添付文書 https://gskpro.com/content/dam/global/hcpportal/ja_JP/products-info/relenza/relenza.pdf
9) Watanabe A, et al:Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis, 51:1167-1175, 2010[PMID:20936975]
10) Damian Garde:Biota Reports Top-Line Data From Its Phase 2 "IGLOO" Trial of Laninamivir Octanoate. 2014 https://www.fiercebiotech.com/biotech/biota-reports-top-line-data-from-its-phase-2-igloo-trial-oflaninamivir-octanoate
11) 第一三共株式会社:イナビル(R)吸入粉末剤20mg添付文書 https://www.medicalcommunity.jp/filedsp/products$druginfo$inavir$pi/field_file_pdf
12) Ison MG, et al:Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza(CAPSTONE-2):a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis, 20:1204-1214, 2020[PMID:32526195]
13) Hayden FG, et al:Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med, 379:913-923, 2018[PMID:30184455]
14) 塩野義製薬株式会社:ゾフルーザ(R)錠 添付文書 https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/340018_6250047F1022_1_14
15) Centers for Disease Control and Prevention:Antiviral Drugs for Seasonal Influenza:Additional Links and Resources. https://www.cdc.gov/flu/professionals/antivirals/links.htm
16) Beutner KR, et al:Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother, 39:1546-1553, 1995[PMID:7492102]
17) グラクソ・スミスクライン株式会社:バルトレックス錠500 添付文書 https://pins.japic.or.jp/pdf/newPINS/00046311.pdf
18) グラクソ・スミスクライン株式会社:ゾビラックス錠 添付文書 https://gskpro.com/content/dam/global/hcpportal/ja_JP/products-info/zovirax/zovirax_tab200.pdf
19) 本田まりこ, 他:ファムシクロビル錠の帯状疱疹に対する臨床効果-アシクロビル錠を対照薬とした追加第III相二重盲検比較試験-. 臨床医薬, 24:825-848, 2008
20) マルホ株式会社:ファムビル(R)錠 添付文書 https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/100898_6250031F1021_1_20
21) マルホ株式会社:アメナリーフの帯状疱疹患者を対象とした第III相二重盲検比較試験<非劣性試験> https://www.maruho.co.jp/medical/articles/amenalief/clinical/index.html
22) Kawashima M & Miyachi Y:A 1-Year Survey of Zoster-Associated Pain after Amenamevir Treatment. Dermatol Ther(Heidelb), 12:1239-1252, 2022[PMID:35501661]
23) アメナリーフ錠200mg:健康被験者を対象としたASP2151の第I相試験(28日間反復投与試験)/15L-CL-019 https://www.pmda.go.jp/drugs/2017/P20170619001/730155000_22900AMX00584_K101_1.pdf
24) マルホ株式会社:アメナリーフ(R)錠200mg 添付文書 https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/730155_6250046F1028_1_06
25) Jayk Bernal A, et al:Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med, 386:509-520, 2022[PMID:34914868]
26) MSD 株式会社:ラゲブリオ(R)カプセル200mg 添付文書 https://www.msdconnect.jp/wp-content/uploads/sites/5/2022/09/pi_lagevrio_cap200.pdf
27) Hammond J, et al:Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med, 386:1397-1408, 2022[PMID:35172054]
28) ファイザー株式会社:パキロビッド(R)パック 添付文書 https://labeling.pfizer.com/ShowLabeling.aspx?id=17209
29) The Liverpool COVID-19 Drug Interactions website https://covid19-druginteractions.org/checker